FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2920258013> ?p ?o ?g. }

• W2920258013 endingPage "328" @default.
• W2920258013 startingPage "323" @default.
• W2920258013 abstract "ObjectivesTo evaluate safety outcomes from clinical studies of a 12-month contraceptive vaginal system (CVS) releasing an average of segesterone acetate (SA) 150 mcg and ethinyl estradiol (EE) 13 mcg daily.Study designWe integrated clinical safety data from nine studies in which women used the CVS for 21 consecutive days and removed it for 7 days of each 28-day cycle. Four studies used the final manufactured CVS, including a 1-year pharmacokinetic study, two 1-year phase 3 trials and a second-year treatment extension study. We assessed safety by evaluating adverse events women reported in a daily diary. We also included data from focused safety studies evaluating endometrial biopsies, vaginal microbiology and liver proteins from one of the phase 3 studies.ResultsThe combined studies included 3052 women; 2308 women [mean age 26.7±5.1 years; mean body mass index (BMI) 24.1±3.7 kg/m2] received the final manufactured CVS, of whom 999 (43.3%) completed 13 cycles of use. Women using the final CVS most commonly reported adverse events of headache (n=601, 26%), nausea (n=420, 18%), vaginal discharge/vulvovaginal mycotic infection (n=242, 10%) and abdominal pain (n=225, 10%). Few (<1.5%) women discontinued for these complaints. Four (0.2%) women experienced venous thromboembolism (VTE), three of whom had risk factors for thrombosis [Factor V Leiden mutation (n=1); BMI>29 kg/m2 (n=2)]. During 21,482 treatment cycles in the phase 3 studies evaluable for expulsion, women reported partial expulsions in 4259 (19.5%) cycles and complete expulsions in 1509 (7%) cycles, most frequently in the initial cycle [499/2050 (24.3%) and 190/2050 (9.3%), respectively]. Safety-focused studies revealed no safety concerns.ConclusionThe 1-year SA/EE CVS has an acceptable safety profile. Additional studies are warranted in obese women at higher risk of VTE.ImplicationsThis 1-year contraceptive vaginal system represents a new long-term, user-controlled and procedure-free option with a safety profile similar to other combination hormonal contraceptives. The same precautions currently used for combination hormonal contraceptive prescriptions apply to this new contraceptive vaginal system." @default.
• W2920258013 created "2019-03-11" @default.
• W2920258013 creator A5017141752 @default.
• W2920258013 creator A5018282082 @default.
• W2920258013 creator A5021933390 @default.
• W2920258013 creator A5027307598 @default.
• W2920258013 creator A5029391740 @default.
• W2920258013 creator A5033378604 @default.
• W2920258013 creator A5034688310 @default.
• W2920258013 creator A5051950292 @default.
• W2920258013 creator A5052640493 @default.
• W2920258013 creator A5053143151 @default.
• W2920258013 creator A5053242908 @default.
• W2920258013 creator A5053919886 @default.
• W2920258013 creator A5066225680 @default.
• W2920258013 creator A5078092789 @default.
• W2920258013 creator A5079473977 @default.
• W2920258013 creator A5081566795 @default.
• W2920258013 creator A5091296451 @default.
• W2920258013 creator A5091310408 @default.
• W2920258013 date "2019-06-01" @default.
• W2920258013 modified "2023-10-17" @default.
• W2920258013 title "Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation" @default.
• W2920258013 cites W1575218991 @default.
• W2920258013 cites W1971811535 @default.
• W2920258013 cites W1979486893 @default.
• W2920258013 cites W2029703729 @default.
• W2920258013 cites W2032380358 @default.
• W2920258013 cites W2041157618 @default.
• W2920258013 cites W2055088544 @default.
• W2920258013 cites W2072872288 @default.
• W2920258013 cites W2106784601 @default.
• W2920258013 cites W2118760305 @default.
• W2920258013 cites W2141965357 @default.
• W2920258013 cites W2151495168 @default.
• W2920258013 cites W2170949963 @default.
• W2920258013 cites W2294236942 @default.
• W2920258013 cites W2521336064 @default.
• W2920258013 cites W2553932163 @default.
• W2920258013 cites W2558994652 @default.
• W2920258013 cites W2615272948 @default.
• W2920258013 cites W2765334263 @default.
• W2920258013 doi "https://doi.org/10.1016/j.contraception.2019.02.001" @default.
• W2920258013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7357828" @default.
• W2920258013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30831102" @default.
• W2920258013 hasPublicationYear "2019" @default.
• W2920258013 type Work @default.
• W2920258013 sameAs 2920258013 @default.
• W2920258013 citedByCount "29" @default.
• W2920258013 countsByYear W29202580132019 @default.
• W2920258013 countsByYear W29202580132020 @default.
• W2920258013 countsByYear W29202580132021 @default.
• W2920258013 countsByYear W29202580132022 @default.
• W2920258013 countsByYear W29202580132023 @default.
• W2920258013 crossrefType "journal-article" @default.
• W2920258013 hasAuthorship W2920258013A5017141752 @default.
• W2920258013 hasAuthorship W2920258013A5018282082 @default.
• W2920258013 hasAuthorship W2920258013A5021933390 @default.
• W2920258013 hasAuthorship W2920258013A5027307598 @default.
• W2920258013 hasAuthorship W2920258013A5029391740 @default.
• W2920258013 hasAuthorship W2920258013A5033378604 @default.
• W2920258013 hasAuthorship W2920258013A5034688310 @default.
• W2920258013 hasAuthorship W2920258013A5051950292 @default.
• W2920258013 hasAuthorship W2920258013A5052640493 @default.
• W2920258013 hasAuthorship W2920258013A5053143151 @default.
• W2920258013 hasAuthorship W2920258013A5053242908 @default.
• W2920258013 hasAuthorship W2920258013A5053919886 @default.
• W2920258013 hasAuthorship W2920258013A5066225680 @default.
• W2920258013 hasAuthorship W2920258013A5078092789 @default.
• W2920258013 hasAuthorship W2920258013A5079473977 @default.
• W2920258013 hasAuthorship W2920258013A5081566795 @default.
• W2920258013 hasAuthorship W2920258013A5091296451 @default.
• W2920258013 hasAuthorship W2920258013A5091310408 @default.
• W2920258013 hasBestOaLocation W29202580131 @default.
• W2920258013 hasConcept C126322002 @default.
• W2920258013 hasConcept C131872663 @default.
• W2920258013 hasConcept C197934379 @default.
• W2920258013 hasConcept C2780221984 @default.
• W2920258013 hasConcept C2780580376 @default.
• W2920258013 hasConcept C2908647359 @default.
• W2920258013 hasConcept C29456083 @default.
• W2920258013 hasConcept C71924100 @default.
• W2920258013 hasConcept C99454951 @default.
• W2920258013 hasConceptScore W2920258013C126322002 @default.
• W2920258013 hasConceptScore W2920258013C131872663 @default.
• W2920258013 hasConceptScore W2920258013C197934379 @default.
• W2920258013 hasConceptScore W2920258013C2780221984 @default.
• W2920258013 hasConceptScore W2920258013C2780580376 @default.
• W2920258013 hasConceptScore W2920258013C2908647359 @default.
• W2920258013 hasConceptScore W2920258013C29456083 @default.
• W2920258013 hasConceptScore W2920258013C71924100 @default.
• W2920258013 hasConceptScore W2920258013C99454951 @default.
• W2920258013 hasFunder F4320306115 @default.
• W2920258013 hasFunder F4320308846 @default.
• W2920258013 hasFunder F4320337364 @default.
• W2920258013 hasIssue "6" @default.
• W2920258013 hasLocation W29202580131 @default.
• W2920258013 hasLocation W29202580132 @default.

• next